Luxor Capital Group's ownership in NeuroSearch has been increased to more than 10%

Announcement
17.05.2011


NeuroSearch A/S (NEUR) has received notification from Luxor Capital Group, LP that the company has increased its ownership in NeuroSearch A/S.

Hereafter, Luxor Capital Group, LP holds more than 2,459,505 shares of DKK 20 nominal value corresponding to an ownership and voting rights of 10.02%.


Patrik Dahlen
CEO


Contact persons:
René Schneider, EVP & CFO, telephone: +45 4460 8700


About NeuroSearch
NeuroSearch A/S is a European based biopharmaceutical company, specialising in CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a pipeline of speciality CNS drugs, including Huntexil^® (pridopidine), a unique orphan drug in Phase III for the treatment of Huntington’s disease. NeuroSearch is building commercial competences with a view to commercialising Huntexil^® through an in-house marketing and sales organisation.

NeuroSearch has a well-established drug discovery division, NsDiscovery, with unique capabilities in the field of ion channels and CNS diseases. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. NeuroSearch also has equity interests in a number of unlisted companies in the Life Science industry.